Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response

Journal of Infectious Diseases

Volumn 181, Issue 2, 2000, Pages 432-441

  Sarrazin, Christoph ^a   Berg, Thomas ^c   Lee, Jung Hun ^a   Rüster, Brigitte ^a   Kronenberger, Bernd ^a   Roth, W Kurt ^b   Zeuzem, Stefan ^a,d  

^a GOETHE UNIVERSITY   (Germany)

^b Inst Transfusionsmedizin I   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; VIRUS PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HEPATITIS C; HUMAN; MALE; PHYLOGENY; PRIORITY JOURNAL; PROTEIN DOMAIN; RELAPSE; TREATMENT OUTCOME;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BINDING SITES; DRUG THERAPY, COMBINATION; EIF-2 KINASE; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS;

EID: 0034101768     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315263     Document Type: Article

References (43)

1. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-905.
2. Serfaty L, Chazouilleres O, Pawlotsky JM, Andreani T, Pellet C, Poupon R. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 1996; 110:291-5.
3. Saito I, Miyamura T, Ohbayashi A, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87:6547-9.
4. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24:778-9.
5. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-92.
6. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic hepatitis C virus. Lancet 1998; 352:1426-32.
7. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest 1995; 96:224-30.
8. Enomoto N, Sakuma U, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334:77-81.
9. Chayama K, Tsubota A, Kobayashi M, et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 1997; 25:745-9.
10. Kurosaki M, Enomoto N, Murakami T, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-α therapy. Hepatology 1997; 25: 750-3.
11. Khorsi H, Castelain S, Wyseur A, et al. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol 1997; 27:72-7.
12. Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 1997; 25:740-4.
13. Hofgärtner WT, Polyak SJ, Sullivan DG, Carithers RL Jr, Gretch DR. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J Med Virol 1997; 53:118-26.
14. Squadrito G, Leone F, Sartori M, et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology 1997; 113:567-72.
15. Sáiz JC, López-Labrador FX, Ampurdanés S, et al. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J Infect Dis 1998; 177:839-47.
16. Sarrazin C, Berg T, Lee JH, et al. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. J Hepatol 1999; 30:1004-13.
17. Duverlie G, Khorsi H, Castelain S, et al. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 1998; 79:1373-81.
18. Gale MJ, Korth MJ, Tang NM, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230:217-27.
19. Gale M Jr, Blakely CM, Kwieciszewski B, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18:5208-18.
20. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21:570-83.
21. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-20.
22. Rüster B, Zeuzem S, Roth WK. Quantification of hepatitis C virus RNA by competitive reverse transcription and polymerase chain reaction using a modified hepatitis C virus RNA transcript. Anal Biochem 1995; 224:597-600.
23. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74:2391-9.
24. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339:237-8.
25. Choo QL, Richman KH, Han JH, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991; 88:2451-5.
26. Kato N, Hijikata M, Ootsuyama Y, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87:9524-8.
27. Okamoto H, Kojima M, Okada S, et al. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 1992; 190:894-9.
28. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673-80.
29. van de Peer Y, De Wachter R. Treecon for Windows: a software package for the construction and drawing of evolutionary trees for the Microsoft Windows environment. Comput Appl Biosci 1994; 10:569-70.
30. Kimura M. The neutral theory of molecular evolution. Cambridge, UK: Cambridge University Press, 1983.
31. Saitou N, Nei M. The neighbor-joining method: a new method for reconstruction phylogenetic tree. Mol Biol Evol 1987; 4:406-25.
32. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985; 39:783-91.
33. Deléage G, Roux B. An algorithm for protein secondary structure prediction based on class prediction. Protein Eng 1987; 1:289-94.
34. Geourjon C, Deléage G. ANTHEPROT 2.0: a three-dimensional module fully coupled with protein sequence analysis methods. J Mol Graph 1995; 13:209-12.
35. Nakashima H, Nishikawa K, Ooi T. The folding type of a protein is relevant to the amino acid composition. J Biochem 1986; 99:153-62.
36. Chou P, Fasman GD. Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol 1978; 47:45-148.
37. Perriere G, Gouy M. WWW-Query: an on-line retrieval system for biological sequence banks. Biochimie 1996; 78:364-9.
38. Tanji Y, Kaneko T, Satoh S, Shimotohno K. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol 1995; 69:3980-6.
39. Frangeul L, Cresta P, Perrin M, et al. Pattern of HCV antibodies with special reference to NS5A reactivity in HCV-infected patients: relation to viral genotype, cryoglobulinemia, and response to interferon. J Hepatol 1998; 28:538-43.
40. Frangeul L, Cresta P, Perrin M, et al. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes. Hepatology 1998; 28:1674-9.
41. Pawlotsky JM, Germanidis G, Neumann AU, Pellerin M, Frainais PO, Dhumeaux D. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations. J Virol 1998; 72:2795-805.
42. Polyak SJ, Paschal DM, McArdle S, Gale MJ Jr, Moradpour D, Gretch DR. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 1999; 29:1262-71.
43. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MMC. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285:107-10.